Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

CytRx Corporation, a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a “significant strategy” in the future design of anti-aging pharmaceuticals.

29 Oct 2009

National study to prevent strokes in children and adolescents with sickle cell anemia

St. Jude Children's Research Hospital investigators were recently awarded a $23 million federal grant to launch a national study of the drug hydroxyurea to prevent first strokes in children and adolescents with sickle cell anemia (SCA).

29 Oct 2009

CHS, BPC and CHEP integrated into one hypertension entity

The Heart and Stroke Foundation of Canada today welcomed the integration of the Canadian Hypertension Society (CHS), Blood Pressure Canada (BPC), and the Canadian Hypertension Education Program (CHEP) into one hypertension entity.

29 Oct 2009

Routine use of HRT increases longevity in postmenopausal women

Hormone replacement therapy (HRT) to treat menopausal estrogen deficiency has been in widespread use for over 60 years. Several observational studies over the years showed that HRT use by younger postmenopausal women was associated with a significant reduction in total mortality; available evidence supported the routine use of HRT to increase longevity in postmenopausal women.

29 Oct 2009

Roche discloses the results of first Phase III clinical study using Taspoglutide

Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s Research.

29 Oct 2009

Proper diet and exercise reduce risk of type 2 diabetes

Intensive lifestyle changes aimed at modest weight loss reduced the rate of developing type 2 diabetes by 34 percent over 10 years in people at high risk for the disease.

29 Oct 2009

Tele-stroke network launched by Wake Forest University Baptist Medical Center

The Comprehensive Stroke Center at Wake Forest University Baptist Medical Center launched a tele-stroke network to help patients in rural communities receive state-of-the-art stroke therapies.

29 Oct 2009

Transient ischemic attacks are treatable and preventable

An estimated 200,000 Americans experience TIAs each year, and more than one-third will later have full strokes. But TIAs, like strokes, are treatable and preventable.

29 Oct 2009

Gene variant may be the cause for bad driving: UC Irvine neuroscientists

Bad drivers may in part have their genes to blame, suggests a new study by UC Irvine neuroscientists.

29 Oct 2009

Sixth round of recipients of Pfizer Cardiovascular Research Awards Program announced

Pfizer Canada is pleased to announce the sixth round of recipients of the Pfizer Cardiovascular Research Awards Program. The program, first launched in October 2005, was developed to fund and support cardiovascular research in Canada.

29 Oct 2009

Moores UCSD Cancer Center awarded $20 million for cancer research

Researchers led by Moores UCSD Cancer Center Director Dennis A. Carson, MD, professor of medicine, and Catriona Jamieson, MD, PhD, assistant professor of medicine and director of the Cancer Stem Cell Research Program at the Moores UCSD Cancer Center have been awarded $20 million over four years to develop novel drugs against leukemia stem cells.

28 Oct 2009

NeuroVasx cPAX Aneurysm Treatment System: first procedure in Spain performed

NeuroVasx, Inc., a medical device company that develops technologies for the treatment of hemorrhagic and ischemic stroke, announced today that the first procedure in Spain utilizing its cPAX Aneurysm Treatment System was performed in Madrid. cPAX received CE Mark earlier this year.

28 Oct 2009

Third-quarter fiscal 2009 results announced by POZEN

POZEN Inc., today announced results for the third quarter ended September 30, 2009.

28 Oct 2009

New CCS guidelines and position papers for physicians and nurse practitioners

Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.

28 Oct 2009

Critical illness insurance, an additional layer of financial protection

As breast cancer awareness month winds to a close and pink ribbons symbolizing the brave fight against this disease take their place on survivors' dressers, the fight continues. Putting the spotlight on this devastating disease has made people think about their own mortality and what would happen if they were diagnosed with a critical illness, says Frank N. Darras, America's top Long Term Disability Lawyer.

28 Oct 2009

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology.

28 Oct 2009

URI scientists discover a new and effective approach for treating cancerous tumor

Two University of Rhode Island associate professors, biophysicists Yana Reshetnyak and Oleg Andreev, have discovered a technology that can detect cancerous tumors and deliver treatment to them without the harming the healthy cells surrounding them, thereby significantly reducing side effects.

27 Oct 2009

GE’s AgileTrac Asset Manager and Enterprise Capacity Management Solution adopted by Virtua Healthcare

Virtua and GE Healthcare announced today that they are collaborating to implement new solutions to help increase efficiencies, lower healthcare costs and improve patient care throughout the health system. Virtua is adopting GE’s AgileTracTM Asset Manager and Enterprise Capacity Management Solution, an automated workflow solution that allows healthcare staff to better track a patient’s inpatient experience, as well as manage the hospital’s assets, ultimately reducing costs and increasing patient satisfaction.

27 Oct 2009

Even one cigarette has serious adverse effects on young adults, says researcher

Even one cigarette has serious adverse effects on young adults, according to research presented by Dr. Stella Daskalopoulou at the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

27 Oct 2009